Delivery Order SPE2DB20D2104-SPE2DB25FMVVZ
- Not listed
- The Defense Logistics Agency awarded a $1,311.62 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order represents a child contract action under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $6,654.43. This non-set-aside, competitively awarded delivery order was executed on August 12, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.42 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single transaction within AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla (apremilast) 30 mg tablets in a quantity of 60 units, valued at $1,311.62. This competitively awarded, firm fixed-price delivery order, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The contract contains no set-aside designation and...
- The Defense Logistics Agency awarded a $7,869.72 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, a pharmaceutical product for treating autoimmune conditions. This competitive award, issued on July 22, 2025, represents a firm fixed-price contract with a completion date of July 23, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- The Defense Logistics Agency awarded a $2,500.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a relatively small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a $36,477.84 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units). The contract is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $43,473.13 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting federal pharmaceutical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $2,691.01 to AmerisourceBergen Drug Corp for 60 tablets of Otezla 30 mg, a pharmaceutical product commonly used to treat psoriasis and psoriatic arthritis. This competitively awarded, firm fixed-price delivery order was executed on July 29, 2025, with an ultimate completion date of July 30, 2025. The contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMVVZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,561.63 to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (quantity: 60) on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This delivery order represents a routine pharmaceutical procurement supporting the Defense Health Agency and broader military healthcare systems. Otezla is an immunosuppressant medication commonly used to treat autoimmune conditions such as psoriasis and psoriatic arthritis. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, maintains a comprehensive product portfolio under its DLA IDC that encompasses specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains serving federal military and healthcare programs globally. The contract structure as a delivery order against an established IDC enables efficient procurement of critical pharmaceutical commodities to support ongoing military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.6k | 7/18/25 |